Medtronic Reports Strong Q1 FY27 Results & Raises Full-Year Guidance
Medtronic plc
Subscribe to track MDT
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Medtronic Reports Strong Q1 FY27 Results & Raises Full-Year Guidance
Company: Medtronic plc (MDT)
Form: 8-K | Filed: September 1, 2026
Significance: Medium
Key Highlights: • Q1 FY27 Worldwide Revenue: $9.756B (+13.7% YoY reported & organic) • GAAP Diluted EPS: $1.14 (+40.7% YoY) | Non-GAAP Diluted EPS: $1.45 (+15.1% YoY) • Raised FY27 Guidance: Organic revenue growth raised to 7.25%–7.75%; Non-GAAP EPS raised to $5.94–$6.00 • Cardiovascular grew 18.9% organically; Neuroscience up 9.3%; Medical Surgical up 10.2%
Market Context: Medtronic delivered broad-based portfolio outperformance and raised full-year fiscal 2027 top-line and bottom-line outlooks amid strong procedural volumes and key product adoption.
Comprehensive Analysis
SEC Filing Analysis: Medtronic plc (NYSE: MDT)
Executive Summary
- Trading Significance: Medium
- Key Takeaway: Medtronic reported robust Q1 FY27 financial results beating guidance midpoints and raised full-year revenue growth and EPS outlooks.
- Market Impact: Favorable operational beat and guidance upward revision indicate strengthening fundamentals across core medtech segments.
Company Information
| Field | Value |
|---|---|
| Company | Medtronic plc |
| Ticker Symbol | MDT |
| CIK | 0001613103 |
| Industry | Electromedical & Electrotherapeutic Apparatus |
Insider Information
| Field | Value |
|---|---|
| Name | N/A (Corporate 8-K Filing) |
| CIK | N/A |
| Title/Position | N/A |
| Relationship | N/A |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 8-K (Item 2.02 - Results of Operations and Financial Condition) |
| Transaction Date | N/A |
| Transaction Code | N/A |
| Security Type | Ordinary Shares |
| Shares Involved | N/A |
| Price Per Share | N/A |
| Total Value | N/A |
| Shares Owned After | N/A |
| Ownership Type | N/A |
Financial & Operational Assessment
Q1 FY27 Performance Overview
- Worldwide Revenue: $9.756 billion, increasing 13.7% YoY (reported and organic), approximately 200 bps above the guidance midpoint.
- Diluted EPS: GAAP EPS rose 40.7% to $1.14; non-GAAP diluted EPS reached $1.45 (+15.1% YoY).
- Segment Growth (Organic):
- Cardiovascular: $3.927 billion (+18.9% organic), driven by Electrophysiology (+29.1%) and Interventional Cardiology (+6.5%).
- Neuroscience: $2.678 billion (+9.3% organic), propelled by Cranial & Spinal Technologies (+12.9%).
- Medical Surgical: $2.279 billion (+10.2% organic), led by Acute Care & Monitoring (+14.2%).
- Diabetes: $843 million (+14.9% organic).
Updated FY27 Guidance
- Organic Revenue Growth: Raised to 7.25% – 7.75% (from prior 6.75% – 7.25%).
- Diluted Non-GAAP EPS: Raised to $5.94 – $6.00 (from prior $5.90 – $6.00).
Market Impact Analysis
- Stock Impact Direction: Positive to Neutral
- Reasoning: A quarterly top- and bottom-line beat combined with raised full-year revenue and earnings guidance provides a solid catalyst for investor sentiment, partially offset by macro considerations and extra fiscal week calendar adjustments ($570M organic benefit).
- Sentiment Indicator: Moderately Bullish / Constructive
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.